What is the evidence on the long-term safety profile of anti-TNF agents in patients with indeterminate colitis compared to those with CD

What is known

- Serious potential long-term adverse effects of anti-TNF in IBD include immunogenicity, opportunistic infections, and melanoma. ¹ - Reported anti-TNF side effects include serious infections, malignancy, worsening of heart failure, and infusion-related reactions. ² - Infliximab safety concerns center on immunosuppression (tumours and infections) and drug-related immunogenicity; the cancer effect remains controversial, prompting latent TB, hepatitis B, and Pneumocystis work-up. ³ - Risk of severe infections was significantly increased in infliximab-treated patients when concomitant steroids were given; long-term data have tempered initial malignancy concerns. ^3,4

What is unknown / caveats

- No excerpt reports safety outcomes specific to indeterminate/unclassified colitis - No head-to-head indeterminate colitis vs Crohn's disease safety comparison in the retrieved evidence - Safety data are drawn from broad IBD, Crohn's, and pediatric cohorts - Whether the anti-TNF safety profile differs meaningfully between indeterminate colitis and Crohn's disease cannot be determined from these excerpts.

## References

1. Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS, Basquill C, Lamb CA, Cameron FL, Murray CD, Parkes M, Gooding I, Ahmad T, Gaya DR, Mann S, Lindsay JO, Gordon J, Satsangi J, Hart A, McCartney S, Irving P, UK Anti-TNF withdrawal study G, Lees CW. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43(8):910-923. PMID: 26892328.

2. Clarke K, Chintanaboina J. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. Clin Rev Allergy Immunol. 2019;57(2):179-193. PMID: 29754190.

3. Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther. 2010;31(5):553-60. PMID: 20002026.

4. MacDonald KV, Pai N, Burow C, deBruyn JC, Huynh HQ, Otley A, Rozario S, Marshall DA. Balancing safety and effectiveness: parent preferences for fecal microbiota transplant and established therapies in pediatric inflammatory bowel disease-results of a multicenter Canadian study. Crohns Colitis 360. 2026;8(1):otag016. PMID: 41878631.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._